Valeant Pharmaceuticals International (NYSE: VRX) is a multi-national, specialty pharmaceutical company that develops, manufactures and markets a broad range of prescription and non-prescription pharmaceutical products primarily in the areas of neurology, dermatology and infectious disease. With a product portfolio of approximately 350 brands, Valeant operates in most major markets around the world. Its worldwide presence reaches more than 100 countries with commercial offices in more than 30 countries, representing most of the top pharmaceutical markets. Valeant's products are sold through three pharmaceutical regions: North America, International (Latin America and Australia), and EMEA (Europe, Middle East and Africa).

Valeant delivers innovative treatments around the world to those whose lives have been affected by disease. In 2007, Valeant's total revenues were $871.4 million, including product sales of $785 million. Based in Aliso Viejo, California, Valeant employs approximately 3,000 people globally. For more information about Valeant Pharmaceuticals International, please visit our corporate Web site at www.valeant.com.